Purpose: To review the role of steroids in the management of uveitic macular edema.
Methods: Review of recent literature on the physiopathology of macular edema and clinical trials involving steroids as main treatment of uveitic macular edema.
Results: The steroid-glucocorticoid receptor complex regulates the action of specific steroids allowing transactivation or repression of a common as well as a unique set of genes. This specificity may help explain differences observed in the side effect profile of commonly used intraocular steroids (dexamethasone, fluocinolone, triamcinolone) whose ability to activate glucocorticoid receptors in model systems is very similar. Sustained delivery devices provide long-term remission of macular edema but with an increased incidence of cataract and glaucoma procedures. The exact incidence is dependent on the specific steroid, the mode of delivery, and the time since injection/placement.Steroid therapy is able to target many important pathways in uveitic macular edema, achieving good clinical results. Secondary adverse effects are still a matter of concern limiting their use.
Conclusions: Steroid therapy remains a mainstay in the management of uveitic macular edema. Local administration precludes systemic adverse effects even though the risk of developing cataract or glaucoma remains an important issue. New slow release devices are thought to improve safety profile while keeping therapeutic advantages.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5301/EJO.2010.6056 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pattern of Uveitis in Northern Vietnam.
Ocul Immunol Inflamm
December 2024
Department of Ophthalmology, Hanoi Medical University, Hanoi, Vietnam.
Purpose: To characterize the spectrum of uveitis in patients visiting three tertiary hospitals in Hanoi, Vietnam.
Methods: This study collected prospective and multicenter data from patients diagnosed with uveitis at three tertiary hospitals in Hanoi City, Vietnam, between January 2022 and January 2024. Data on age, sex, clinical and laboratory findings, and etiology were collected.
Long-Term Treatment Outcomes of Micropulse Transscleral Cyclophotocoagulation in Primary and Secondary Glaucoma: A 5-Year Analysis.
Ophthalmol Ther
December 2024
University Eye Clinic Maastricht, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.
Introduction: To investigate 5-year outcomes on intraocular pressure (IOP) and safety of micropulse transscleral cyclophotocoagulation (TSCPC) in patients with glaucoma.
Methods: Patients with mild to advanced glaucoma who underwent a standardized micropulse TSCPC procedure at the University Eye Clinic Maastricht from November 2016 to February 2019 were included.
Results: A total of 165 eyes were included, with outcomes for 112 eyes available after 5-year follow-up.
Suprachoroidal Triamcinolone Acetonide for Noninfectious Uveitis: Real-World Impact on Clinical Outcomes.
Am J Ophthalmol
December 2024
From the Department of Ophthalmology & Vision Science, University of California (K.P., A.H., P.E.-N., G.Y., K.M.), Davis, Sacramento, California, USA. Electronic address:
Article Synopsis
- The study aimed to assess the effects of suprachoroidal triamcinolone acetonide (TA) injections on patients with noninfectious uveitis, focusing on key outcomes like central subfield thickness (CST) and visual acuity.
- Data was collected from 61 eyes of 51 patients over two years, revealing a significant reduction in CST from 437.61 microns to 348.17 microns within 6 weeks following treatment, along with an improvement in fluorescein angiography scores.
- Results showed that while some patients needed additional treatment for macular edema over time, 41.2% of those followed for 24 weeks did not require further interventions, and
Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial-24-week Outcomes of Uveitic Macular Edema Retreatment.
Ophthalmology
November 2024
Center for Clinical Trials and Evidence Synthesis, Departments of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA; Department of Ophthalmology, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Purpose: Evaluation of longer-term effectiveness of three intravitreal therapies (methotrexate, ranibizumab, or dexamethasone implant) for participants enrolled in the randomized comparative effectiveness trial the Macular Edema Ranibizumab versus Intravitreal anti-inflammatory Therapy (MERIT) Trial followed for24 weeks.
Design: Multicenter randomized controlled clinical trial with masked evaluation of retinal thickness and visual acuity.
Participants: Patients with persistent or recurrent uveitic macular edema.
Review on the Use of Difluprednate in Inflammatory Eye Disorders: The Topical Steroid That Goes the Distance.
Ocul Immunol Inflamm
November 2024
Department of Ophthalmology, Hadassah Medical Center, Jerusalem, Israel.
Difluprednate (DFP) (difluoroprednisolone butyrate acetate, or DFBA) ophthalmic emulsion 0.05% (Durezol®) was the first potent corticosteroid to be approved for both postoperative pain and inflammation in 2008. In June 2012, it was approved for the treatment of endogenous anterior uveitis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!